These results confirm in a case study that YURVAC® RHD is a suitable and distinctive solution to control RHD outbreaks in the field. The performance of YURVAC® RHD was better than that of Vaccine-A. 

In conclusion, YURVAC® RHD demonstrated superior efficacy in controlling RHD outbreaks compared to Vaccine-A under real-world socio-economic conditions. The findings contribute valuable insights into the comparative efficacy of vaccines under real-world socio-economic conditions, emphasizing the importance of tailored vaccination strategies for optimal disease management.